Global Oral Anti-Diabetic Drugs Market: World Market Review and Analysis By Type, By Region, By Country (2019 Edition): Opportunities and Forecast (2019-2024)

October 2019 | 275 pages | ID: G02F7D4E0680EN
Azoth Analytics

Abstracts

EXECUTIVE SUMMARY

The Oral anti diabetes drug was valued at USD 25.6 Billion in the year 2018. Over the recent years, oral anti-diabetes drug has been witnessing considerable growth on the back of rising incidences of diabetes, growing geriatric population, growing government initiatives, and continuous research and development conducted by pharmaceutical manufacturers. In addition, growing sedentary lifestyle, presence of diabetes medicines in the Essential drug List of the nations and wide insurance coverage for diabetes drugs have contributed to the growth rate of Oral anti-diabetes drugs. These factors are anticipated to provide higher momentum to the market growth in the forecast period. However, preferred use of insulin over oral anti diabetes drugs and the complications associated with the drugs has been hindering the market growth.

Among all the types of oral anti-diabetes drugs that includes Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor and Thiazolidinedione, Biguanides holds the highest market share in the Oral Anti-diabetic drug Market owing to its proven benefits in the treatment of diabetes mellitus.

Among the regions, North America Oral Anti-diabetic drug Market will continue to be the largest market in the forecast period, majorly driven by favourable government reimbursement policies in addition to high healthcare awareness. Countries such as India, China, Brazil are a lucrative market for Oral Anti-diabetic drugs Market.

SCOPE OF THE REPORT

Global Oral Anti-Diabetes Drugs Market (Actual Period: 2014-2018, Forecast Period: 2019-2024)

• Oral Anti-Diabetes Drugs Market – Size, Growth, Forecast
• Analysis by Type: Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor, Thiazolidinediones, Others

Regional Oral Anti-Diabetes Drugs Market - North America, Europe, APAC, ROW (Actual Period: 2014-2018, Forecast Period: 2019-2024)

• Oral Anti-Diabetes Drugs Market – Size, Growth, Forecast
• Analysis by Type: Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor, Thiazolidinediones, Others

Country Analysis - U.S. Canada, U.K., Germany, France, Italy, India, Japan, China, Brazil (Actual Period: 2014-2018, Forecast Period: 2019-2024)

• Oral Anti-Diabetes Drugs Market – Size, Growth, Forecast
• Analysis by Type: Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor, Thiazolidinediones, Others

Company Analysis – Novartis, Pfizer, Sanofi, Merck & Co., AstraZeneca, Janssen Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Takeda Pharmaceutical.

Other Report Highlights

• Competitive Landscape – Sales, Segments, Market Share
• Leading Companies
• Non generic drug analysis
• Market Dynamics – Drivers and Restraints.
• Market Trends
• Porter Five Forces Analysis.
• SWOT Analysis.

CUSTOMIZATION OF THE REPORT

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.

Contents

1. RESEARCH METHODOLOGY

2. EXECUTIVE SUMMARY

3. STRATEGIC RECOMMENDATIONS

4. ORAL ANTI-DIABETIC DRUGS MARKET: PRODUCT OUTLOOK

5. GLOBAL ORAL ANTI-DIABETIC DRUGS MARKET: GROWTH AND FORECAST

5.1 By Value (2014-2018)
5.2 By Value (2019-2024)

6. GLOBAL ORAL ANTI-DIABETIC DRUGS MARKET: SEGMENT ANALYSIS

6.1 Global Oral Anti-diabetic drug Market Size, By Type: Breakdown (%)
  6.1.1 Global Oral Anti-diabetic drug Market Size, By Type, 2018 (%)
  6.1.2 Global Oral Anti-diabetic drug Market Size, By Type, 2024 (%)
6.2 Global Biguanides Oral Anti-diabetic drug Market, By Value (2014-2024)
6.3 Global Sulfonylureas Oral Anti-diabetic drug Market, By Value (2014-2024)
6.4 Global Thiazolidinediones Oral Anti-diabetic drug Market, By Value (2014-2024)
6.5 Global Alpha- glucosidase inhibitors Oral Anti-diabetic drug Market, By Value (2014-2024)
6.6 Global Dipeptidyl peptidase IV inhibitor Oral Anti-diabetic drug Market, By Value (2014-2024)
6.7 Global Sodium Glucose Co- transporter-2 inhibitor Oral Anti-diabetic drug Market, By Value (2014-2024)
6.8 Global Others Oral Anti-diabetic drug Market, By Value (2014-2024)
6.9 Global Oral Anti-diabetic drug Market: Market Attractiveness, By Type

7. GLOBAL ORAL ANTI-DIABETIC DRUGS MARKET: REGIONAL ANALYSIS

7.1 Global Oral Anti-diabetic drug Market Size, By Region : Breakdown (%)
  7.1.1 Global Oral Anti-diabetic drug Market Size, By Region, 2018 (%)
  7.1.2 Global Oral Anti-diabetic drug Market Size, By Region, 2024 (%)
7.2 North America Oral Anti-diabetic drug Market: Growth and Forecast
  7.2.1 By Value (2014-2018)
  7.2.2 By Value (2019-2024)
  7.2.3 North America Oral Anti-diabetic drug Market: Major Market Players
  7.2.4 By Type, By Value (2014-2018)
  7.2.5 By Type, By Value (2019-2024)
7.3 North America Oral Anti-Diabetic Drugs Market: Country Analysis (U.S and Canada)
7.4 Market Attractiveness of North America Oral Anti-diabetic drug Market – By Country
  7.4.1 U.S Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.4.2 U.S Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.4.3 U.S Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
  7.4.4 Canada Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.4.5 Canada Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.4.6 Canada Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
7.5 Europe Oral Anti-diabetic drug Market: Growth and Forecast
  7.5.1 By Value (2014-2018)
  7.5.2 By Value (2019-2024)
  7.5.3 Europe Oral Anti-diabetic drug Market: Major Market players
  7.5.4 By Type, By Value (2014-2018)
  7.5.5 By Type, By Value (2019-2024)
7.6 Europe Oral Anti-diabetic drug Market: Country Analysis (U.K and Germany)
7.7 Market Attractiveness of Europe Oral Anti-Diabetic Drugs Market – By Country
  7.7.1 U.K Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.7.2 U.K Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.7.3 U.K Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
  7.7.4 Germany Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.7.5 Germany Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.7.6 Germany Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
  7.7.7 France Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.7.8 France Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.7.9 France Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
  7.7.10 Italy Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.7.11 Italy Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.7.12 Italy Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
7.8 APAC Oral Anti-Diabetic Drugs Market: Growth and Forecast
  7.8.1 By Value (2014-2018)
  7.8.2 By Value (2019-2024)
  7.8.3 APAC Oral Anti-diabetic drug Market: Major Market Players
  7.8.4 By Type, By Value (2014-2018)
  7.8.5 By Type, By Value (2019-2024)
7.9 APAC Oral Anti-diabetic drug Market: Country Analysis (Japan, India and China)
7.10 Market Attractiveness of APAC Oral Anti-diabetic drug Market – By Country
  7.10.1 India Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.10.2 India Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.10.3 India Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
  7.10.4 Japan Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.10.5 Japan Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.10.6 Japan Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
  7.10.7 China Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.10.8 China Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.10.9 China Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)
7.11 ROW Oral Anti-Diabetic Drugs Market: Growth and Forecast
  7.11.1 By Value (2014-2018)
  7.11.2 By Value (2019-2024)
  7.11.3 By Type, By Value (2014-2018)
  7.11.4 By Type, By Value (2019-2024)
7.12 ROW Oral Anti-diabetic drug Market: Country Analysis (Brazil)
  7.12.1 Brazil Oral Anti-diabetic drug Market, By Value (2014-2024)
  7.14.2 Brazil Oral Anti-diabetic drug Market, By Type, By Value (2014-2018)
  7.14.3 Brazil Oral Anti-diabetic drug Market, By Type, By Value (2019-2024)

8. GLOBAL ANTI-DIABETIC DRUGS MARKET: COMPETITIVE LANDSCAPE

8.1 Company Share Analysis
8.2 Drug Analysis

9. GLOBAL ORAL ANTI-DIABETIC DRUGS MARKET DYNAMICS

9.1 Global Oral Anti-Diabetic Drugs Market Drivers
9.2 Global Oral AAnti-Diabetic Drugs Market Restraints
9.3 Global Oral Anti-Diabetic Drugs Market Trends
9.4 Porter Five Force Analysis
9.5 SWOT Analysis
9.6 Policy and Regulatory Landscape

10. COMPANY PROFILES

10.1 Novartis
10.2 Pfizer
10.3 Sanofi
10.4 Takeda Pharmaceuticals
10.5 Merck & Co.
10.6 AstraZeneca
10.7 Janssen Pharmaceutical
10.8 Boehringer Ingelheim
10.9 Eli Lilly

11.ABOUT US

List Of Figures

LIST OF FIGURES

Figure 1:Global Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
Figure 2:Global Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Figure 3:Worldwide Diabetes Prevalence
Figure 4:Prescribed diabetes medications globally
Figure 5:Drug spending pattern, By top 10 therapy classes, In 2018
Figure 6:Population ages 65 and above, By Select Region, 2013-2017 (% of total)
Figure 7:Projected global population aged 60 years & above (In Billions)
Figure 8:Projected global population (In Billions)
Figure 9:Undiagnosed cases of diabetes (20-79 years), By Region, In 2017
Figure 10:Top 10 countries with diabetic population along with their healthcare expenditure, In 2017, In Million
Figure 11:Deaths attributable to diabetes, In 2017
Figure 12:Total healthcare expenditure and mean healthcare expenditure per person and per income group, In 2017
Figure 13:Global Oral Anti-diabetic drug Market Size, By Type, 2018 (%)
Figure 14:Global Oral Anti-diabetic drug Market Size, By Type, 2024F (%)
Figure 15:Global Oral Anti-diabetic drug Market Size, By Type, 2018 (In %)
Figure 16:Global Oral Anti-diabetic drug Market Size, By Type, 2024 (In %
Figure 17:Global Biguanides Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 18:Global Biguanides Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
Figure 19:Global Sulfonylurease Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 20:Global Sulfonylurease Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
Figure 21:Global TZDs Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 22:Global TZDs Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
Figure 23:Global ? Glucosidase Inhibitors Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 24:Global ? Glucosidase Inhibitors Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
Figure 25:Global DPP-4 Inhibitors Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 26:Global DPP-4 Inhibitors Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
Figure 27:Global SGL2 Inhibitors Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 28:Global SGL2 Inhibitors Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
Figure 29:Global Others Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 30:Global Others Oral Anti-diabetic drug Market, By Value, Forecast, 2019-2024(USD Million)
Figure 31:Market Opportunity Chart of global Oral Anti-diabetic drug Market - By Type, By Value (Year - 2024)
Figure 32:Global Healthcare Landscape, By Select Region
Figure 33: Global Oral Anti-diabetic drug Market Size, By Region, 2018 (%)
Figure 34:Global Oral Anti-diabetic drug Market Size, By Region, 2024 (%)
Figure 35:North America Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
Figure 36:North America Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Figure 37:Prevalence of diabetes in North America, By age and sex, In 2017
Figure 38:Prevailing diabetes trend in North America
Figure 39:Top 5 countries with diabetic patients in North America and Caribbean Region, In 2017
Figure 40:North America population aged 65 and above, 2013-2018 (% of total)
Figure 41:Prevalence of Diabetes in North America, 2017 & 2045E (In Million)
Figure 42:North America GDP, 2012-2017 (USD Trillion)
Figure 43:North America GDP per capita, current prices, 2013-2023F (In USD)
Figure 44:Competitive Positions of Select Companies Operating in North America Oral Anti-diabetic drug Market (2018)
Figure 45:North America Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 46:North America Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 47:North America Oral Anti-diabetic drug Market Size, By Country, 2018 (%)
Figure 48:North America Oral Anti-diabetic drug Market Size, By Country, 2024F (%)
Figure 49: Market Opportunity Chart of North America Oral Anti-diabetic drug Market - By Type, By Value (Year - 2024)
Figure 50:USA Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 51:USA Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Figure 52:U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Figure 53:Prevalence of diabetes in United States, 2013-2017, In million
Figure 54:U.S., Percentage of diabetic patients afflicted from other consequences as of 2017 (in %)
Figure 55:U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
Figure 56:U.S., Population ages 65 and above, 2013-2017 (% of total)
Figure 57:U.S., Population ages 65 and above, Forecast (In Millions)
Figure 58:U.S. Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 59:U.S. Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 60:Canada Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 61:Canada Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Figure 62:Prevalence of diabetes in Canada, 2013-2017,In million
Figure 63:Health insurance coverage plans for diabetic patients
Figure 64:Prevalence of Diabetics in Canada, (% of Total Population) 2015 & 2045E
Figure 65: Estimated Prevalence of Pre-Diabetics in Canada, (% of Total Population) 2015 & 2045E
Figure 66:Overweight and Obese Population in Canada, 2015-2017 (% of total)
Figure 67:Canada, Expenditure on Health as a share of GDP, 2012-2017 (In %)
Figure 68:Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 69:Canada, Population ages 65 and above, 2012-2018 (% of total)
Figure 70:Canada Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 71:Canada Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 72:Europe Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
Figure 73:Europe Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Figure 74:Prevalence of Diabetes (Age 18+), 2017 & 2045E (In Million)
Figure 75:Diabetes Prevalence (% of population ages 20 to 79), By Select Country, 2017
Figure 76:Prevalence of Diabetes Among Children, 2017
Figure 77:Obesity Rate, By Select Country, 2017 (In Percentage)
Figure 78:European Union, Population ages 65 and above, 2013-2018 (% of total)
Figure 79:Per Capita Health Expenditure, By Select Country, 2018 (USD)
Figure 80:European Country Population Aged 65 and Above, 2012-2017 (% of Total)
Figure 81: GDP, Europe Region, By Select Country, 2017 (In Trillion USD)
Figure 82:Competitive Positions of Select Companies Operating in Europe Oral Anti-diabetic drug Market (2018)
Figure 83:Europe Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 84:Europe Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 85:Europe Oral Anti-diabetic drug Market Size, By Country, 2018 (%)
Figure 86:Europe Oral Anti-diabetic drug Market Size, By Country, 2024F (%)
Figure 87:Market Opportunity Chart of Europe Oral Anti-diabetic drug Market - By Type, By Value (Year - 2024)
Figure 88:U.K. Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 89:U.K. Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Figure 90:U.K, Pharmaceutical R&D Spending, Euro Million, 2013-2016
Figure 91:Number of deaths in United Kingdom by diabetes, By sex and age, In 2017
Figure 92:U.K, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
Figure 93:U.K, Population Ages 65 and Above (% of total), 2012-2018
Figure 94:Prevalence of diabetes in United Kingdom, 2013-2017, In million
Figure 95:U.K. Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 96:U.K. Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 97: Germany Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 98:Germany Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Figure 99:German Pharmaceutical companies expenditure on R&D, In Million Euros
Figure 100:Healthcare spending pattern in Germany, In 2018, In USD $
Figure 101:Health insurance coverage in Germany, In 2018
Figure 102:Germany, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
Figure 103:Germany, Population ages 65 and above, 2012-2018 (% total)
Figure 104:Germany Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 105:Germany Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 106:France Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 107:France Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Figure 108:Prevalence of diabetes in France, 2013-2017, In million
Figure 109:Prevalence of diabetes and related risk factors in France, In 2017
Figure 110:France, Population Ages 65 and Above (% of total), 2012-2018
Figure 111:France, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 112:Healthcare expenditure in France (as a % of GDP)
Figure 113: Healthcare spending pattern in France, In 2016 & 2050, In USD $
Figure 114:France Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 115:France Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 116:Italy Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 117:Italy Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Figure 118:Italy, Health Expenditure, (% of GDP), 2013-2017 (USD)
Figure 119:Prevalence of diabetes in Italy, 2013-2017, In million
Figure 120:Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 121:Italy, Population Ages 65 and Above (% of total), 2012-2018
Figure 122:Italy Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 123:Italy Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 124:APAC Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
Figure 125:APAC Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Figure 126:Population ages 65 and above, APAC Region, By Select Countries, 2018 (% of total)
Figure 127:Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
Figure 128:APAC, GDP, By Select Country, 2017 (In USD Trillion)
Figure 129: Diabetes Prevalence (% of population ages 20 to 79), By Select Country, 2018
Figure 130:Obesity Rate, By Select Country, 2017 (In Percentage)
Figure 131:Competitive Positions of Select Companies Operating in Asia Pacific Oral Anti-diabetic drug Market (2018)
Figure 132:APAC Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 133:APAC Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 134:APAC Oral Anti-diabetic drug Market Size, By Country, 2018 (%)
Figure 135:APAC Oral Anti-diabetic drug Market Size, By Country, 2024F (%)
Figure 136:Market Opportunity Chart of APAC Oral Anti-diabetic drug Market - By Type, By Value (Year - 2024)
Figure 137:India Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 138:India Oral Anti-diabetic drug Market, By Value, 2019-2024 (USD Million)
Figure 139:Prevalence of diabetes in India, In million
Figure 140:India, Population ages 65 and above, 2013-2018, In Million
Figure 141:India, Share of Urban Population, 2012-2018 (In %)
Figure 142:India, GDP Growth Per Year, 2015-2019 (In %)
Figure 143:India, Total Population, 2013-2023F (In Million)
Figure 144:India Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 145: India Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 146:Japan Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 147:Japan Oral Anti-diabetic drug Market, By Value, 2019-2024 (USD Million)
Figure 148:Prevalence of diabetes in Japan, In million
Figure 149:Japan Healthcare Expenditure Outlook (2017) (%)
Figure 150:Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 151:Japan, Population ages 65 and above, 2012-2017 (% of total)
Figure 152:Japan Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 153:Japan Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 154:China Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 155:China Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Figure 156:China, Population ages 65 and above, 2012-2018 (% of total)
Figure 157:China Healthcare Expenditure Outlook (2018) (%)
Figure 158:Prevalence of diabetes in China, In million
Figure 159:China, Share of Urban Population, 2012-2018 (In %)
Figure 160:China, GDP Growth Per Year, 2015-2019 (In %)
Figure 161: China, Total Population, 2013-2021F (In Million)
Figure 162:China Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 163:China Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 164:ROW Oral Anti-diabetic drug Market Size, By Value, 2014-2018 (USD Million)
Figure 165:ROW Oral Anti-diabetic drug Market Size, By Value, Forecast, 2019-2024 (USD Million)
Figure 166:Population ages 65 and above, By Select Country, 2017 (% of total)
Figure 167:Population ages 60 and above, By Select Country, 2050 (% of total)
Figure 168:Latin America and Caribbean, Population ages 65 and above 2012-2018 (% of total)
Figure 169:Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2018
Figure 170:Middle East and North Africa, Population ages 65 and above (% of total)
Figure 171:Middle East and North Africa, GDP, 2012-2018 (In USD Trillion)
Figure 172:Prevalence of diabetes in Latin America ad Caribbean, In million
Figure 173:Prevalence of diabetes in Middle East and North Africa, In million
Figure 174:ROW Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 175:ROW Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 176:ROW Oral Anti-diabetic drug Market Size, By Country, 2018 (%)
Figure 177: ROW Oral Anti-diabetic drug Market Size, By Country, 2024F (%)
Figure 178:Brazil Oral Anti-diabetic drug Market, By Value, 2014-2018 (USD Million)
Figure 179:Brazil Oral Anti-diabetic drug Market, By Value, 2019-2024(USD Million)
Figure 180:Brazil, Population ages 65 and above, 2012-18 (% of total)
Figure 181:Brazil, GDP, 2012-2018 (In USD Trillion)
Figure 182:Prevalence of diabetes in Brazil, In million
Figure 183:Brazil health expenditure as a share of GDP, 2018
Figure 184:Brazil Oral Anti-diabetic drug Market: By Type, By Value, 2014-2018 (USD Million)
Figure 185:Brazil Oral Anti-diabetic drug Market: By Type, By Value, 2019-2024 (USD Million)
Figure 186:Global Market Share of Leading Companies, By Select Company, 2018 (In %)
Figure 187:Growth of non generic oral diabetic drugs
Figure 188:Novartis, Net Sales, 2015-2018 (In Billion USD)
Figure 189:Galvus, Net Sales, 2014-2018 (In Billion USD)
Figure 190:Novartis, Sales, By Innovative Medicine Segment, FY ended March 2018 (%)
Figure 191:Novartis, Sales, By Innovative Medicine Segment, FY ended March 2018 (%)
Figure 192:Pfizer, Sales Revenue, 2014-2018 (USD million)
Figure 193: Pfizer, Sales, By Business Segment, FY ended March 2018 (In %)
Figure 194:Pfizer, By Geographic Region, FY ended March 2017 (In %)
Figure 195:Sanofi Annual Sales Revenue of Cardiac and Vascular Group,2014-2018 (USD Million)
Figure 196:Sanofi , Sales, By Business Segment, FY ended March 2018 (%)
Figure 197:Sanofi, By Region, FY ended March 2018 (%)
Figure 198: Sanofi Annual Sales Revenue of Amaryl ,2014-2018 (USD Million)
Figure 199:Sanofi, Amaryl Sales, By Region, FY ended March 2018 (%)
Figure 200:Takeda, Net Sales, 2014-2018 (In Million USD)
Figure 201:Nesina, Net Sales, 2014-2018 (In Million USD)
Figure 202:Takeda, Net Sales, By Geographic Region, 2018 (In %)
Figure 203:Nesina, Net Sales, By Geographic Region, 2018 (In %)
Figure 204:Merck & Co., Net Sales, 2014-2018 (In Billion USD)
Figure 205:Januvia, Net Sales, 2014-2018 (In Billion USD)
Figure 206:Janumet, Net Sales, 2014-2018 (In Billion USD)
Figure 207:Januvia, Net Sales, By Geographic Region, 2018 (In %)
Figure 208:Janumet, Net Sales, By Geographic Region, 2018 (In %)
Figure 209: Farxiga, Net Sales, 2014-2018 (In Million USD)
Figure 210:Onglyza, Net Sales, 2014-2018 (In Million USD)
Figure 211:Farxiga, Net Sales, By Geographic Region, 2018 (In %)
Figure 212:Onglyza, Net Sales, By Geographic Region, 2018 (In %)
Figure 213:Janssen Pharmaceutical, Cardiovascular segment, Net Sales, 2014-2018 (In Million USD)
Figure 214:Invokana, Net Sales, 2014-2018 (In Million USD)
Figure 215:Cardiovascular segment, Net Sales, By Geographic Region, 2018 (In %)
Figure 216:Invokana, Net Sales, By Geographic Region, 2018 (In %)
Figure 217:Jardiance, Net Sales, 2017-2018 (In Million USD)
Figure 218:Trajenta, Net Sales, 2017-2018 (In Million USD)
Figure 219:Jardiance, Net Sales, 2016-2018 (In Million USD)
Figure 220:Trajenta & Jentadueto, Net Sales, 2014-2018 (In Million USD)
Figure 221:Jardinace, Net Sales, By Geographic Region, 2018 (In %)
Figure 222:Trajenta & Jentadueto, Net Sales, By Geographic Region, 2018 (In %)

List Of Tables

LIST OF TABLES

Table A:Most common oral anti- diabetic drugs prescribed in United States
Table B:Prescription drugs insurance coverage provided by Medicare Part D in United States
Table C:Prescription drug coverage plans in Canada
Table D:Most common oral anti- diabetic drugs prescribed in Canada
Table E:Combinational oral anti- diabetic drugs prescribed in Canada
Table F:Reimbursement criteria for prescription drugs in Europe
Table G:Most common oral anti- diabetic drugs prescribed in Canada
Table H:U.K. employees co-payment plan for prescription drugs at local pharmacies
Table I:Prevalence of diabetes and related risk factors in United Kingdom
Table J:Germany, Healthcare Related Statistics, 2017
Table K:Top 5 countries with number of diabetic people across Europe, In million, In 2017
Table L:Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
Table M:Drivers driving Indian Pharmaceutical industry
Table N:Diabetes medications in India’s National @List of Essential medicines
Table O:Healthcare expenditure pattern in Middle East and North Africa, In 2017
Table P:Pharmaceutical expenditure in relation to healthcare expenditure in Middle East and North Africa, In 2017
Table Q:Healthcare spending pattern in Brazil (In USD)